Mathur S, Corbridge T, Packnett E, Jariwala-Parikh K, Deb A
Allergy Asthma Clin Immunol. 2024; 20(1):56.
PMID: 39449041
PMC: 11515424.
DOI: 10.1186/s13223-024-00917-4.
Al-Ahmad M, Ali A, Maher A
BMC Pulm Med. 2023; 23(1):490.
PMID: 38053108
PMC: 10699072.
DOI: 10.1186/s12890-023-02786-w.
Nieto A, El-Sayed Z, Gomez R, Hossny E, Jiu-Yao W, Kalayci O
World Allergy Organ J. 2023; 16(11):100837.
PMID: 38020283
PMC: 10656246.
DOI: 10.1016/j.waojou.2023.100837.
Zhang Z, Sun Y, Chen S
Front Pharmacol. 2023; 14:1095737.
PMID: 37361219
PMC: 10285082.
DOI: 10.3389/fphar.2023.1095737.
Rojo-Tolosa S, Sanchez-Martinez J, Pineda-Lancheros L, Galvez-Navas J, Gonzalez-Gutierrez M, Jimenez-Galvez G
Int J Mol Sci. 2023; 24(8).
PMID: 37108192
PMC: 10139019.
DOI: 10.3390/ijms24087029.
Cytokine-targeted therapies for asthma and COPD.
Schleich F, Bougard N, Moermans C, Sabbe M, Louis R
Eur Respir Rev. 2023; 32(168).
PMID: 37076177
PMC: 10113955.
DOI: 10.1183/16000617.0193-2022.
Association of general and abdominal obesity with lung function, FeNO, and blood eosinophils in adult asthmatics: Findings from NHANES 2007-2012.
Zhang H, Hu Z, Wang S, Xu J, Li S, Song X
Front Physiol. 2023; 14:1019123.
PMID: 36846327
PMC: 9950393.
DOI: 10.3389/fphys.2023.1019123.
Baseline Characteristics of Patients Enrolled in Clinical Trials of Biologics for Severe Asthma as Potential Predictors of Outcomes.
Menzella F
J Clin Med. 2023; 12(4).
PMID: 36836079
PMC: 9960148.
DOI: 10.3390/jcm12041546.
Airway smooth muscle function in asthma.
Xiong D, Martin J, Lauzon A
Front Physiol. 2022; 13:993406.
PMID: 36277199
PMC: 9581182.
DOI: 10.3389/fphys.2022.993406.
Management of Uncontrolled Asthma: A Framework for Novel and Legacy Biologic Treatments.
Tan L, Nguyen N, Alismail A, Castro M
J Asthma Allergy. 2022; 15:875-883.
PMID: 35791394
PMC: 9250774.
DOI: 10.2147/JAA.S369836.
A pragmatic guide to choosing biologic therapies in severe asthma.
Kavanagh J, Hearn A, Jackson D
Breathe (Sheff). 2022; 17(4):210144.
PMID: 35296105
PMC: 8919802.
DOI: 10.1183/20734735.0144-2021.
The use of biologics in personalized asthma care.
Watchorn D, Holguin F
Expert Rev Clin Immunol. 2021; 17(12):1301-1309.
PMID: 34767743
PMC: 8822729.
DOI: 10.1080/1744666X.2021.2006635.
Variability of 2 inflammatory markers guiding biologic therapy of severe asthma: A 5-year retrospective study from a single tertiary hospital.
Li H, Zhang Q, Wang J, Gao S, Li C, Wang J
World Allergy Organ J. 2021; 14(9):100547.
PMID: 34611471
PMC: 8463912.
DOI: 10.1016/j.waojou.2021.100547.
Indirect comparison of efficacy of dupilumab mepolizumab and omalizumab for severe type 2 asthma.
Praetorius K, Henriksen D, Schmid J, Printzlau P, Pedersen L, Madsen H
ERJ Open Res. 2021; 7(3).
PMID: 34476242
PMC: 8405862.
DOI: 10.1183/23120541.00306-2021.
Biological therapy for severe asthma.
Dragonieri S, Carpagnano G
Asthma Res Pract. 2021; 7(1):12.
PMID: 34389053
PMC: 8362167.
DOI: 10.1186/s40733-021-00078-w.
Asthma and Chronic Rhinosinusitis: How Similar Are They in Pathogenesis and Treatment Responses?.
Matucci A, Bormioli S, Nencini F, Chiccoli F, Vivarelli E, Maggi E
Int J Mol Sci. 2021; 22(7).
PMID: 33805199
PMC: 8037977.
DOI: 10.3390/ijms22073340.
Management of severe asthma: summary of the European Respiratory Society/American Thoracic Society task force report.
Khurana S, Bush A, Holguin F
Breathe (Sheff). 2020; 16(2):200058.
PMID: 33304407
PMC: 7714544.
DOI: 10.1183/20734735.0058-2020.
Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma.
Henriksen D, Bodtger U, Sidenius K, Maltbaek N, Pedersen L, Madsen H
Allergy Asthma Clin Immunol. 2020; 16:49.
PMID: 32565844
PMC: 7302157.
DOI: 10.1186/s13223-020-00442-0.
Measuring inflammation in paediatric severe asthma: biomarkers in clinical practice.
Licari A, Manti S, Castagnoli R, Leonardi S, Marseglia G
Breathe (Sheff). 2020; 16(1):190301.
PMID: 32494300
PMC: 7249787.
DOI: 10.1183/20734735.0301-2019.
Aeroallergen Sensitization, Serum IgE, and Eosinophilia as Predictors of Response to Omalizumab Therapy During the Fall Season Among Children with Persistent Asthma.
Sheehan W, Krouse R, Calatroni A, Gergen P, Gern J, Gill M
J Allergy Clin Immunol Pract. 2020; 8(9):3021-3028.e2.
PMID: 32376491
PMC: 8775809.
DOI: 10.1016/j.jaip.2020.03.051.
